Treatment of hepatitis C virus infection in the future

Clinical and Translational Medicine

Tatsuo Kanda¹  Osamu Yokosuka¹  Masao Omata² 

[1] Department of Gastroenterology and NephrologyChiba UniversityGraduate School of Medicine1‐8‐1 Inohana260‐8670Chuo‐kuChibaJapan;Yamanashi Hospitals (Central and Kita) Organization1‐1‐1 Fujimi400‐8506Kofu‐shiYamanashiJapan;

关键词: HCV;    Telaprevir;    Boceprevir;    Sofosbuvir;    Daclatasvir;   

DOI  :  10.1186/2001-1326-2-9

来源: DOAJ

【 摘 要 】

Abstract Two direct‐acting antivirals (DAAs) against hepatitis C virus (HCV): telaprevir and boceprevir, are now available in combination with peginterferon plus ribavirin for the treatment of chronic hepatitis C infection. Although these drugs are potent inhibitors of HCV replication, they occasionally result in severe adverse events. In the present clinical trials, in their stead, several second‐generation DAAs are being investigated. Most of them are being viewed with high expectations, but they also require the combination with peginterferon plus ribavirin. In the near future, we might be using all‐oral DAAs and interferon‐free regimens for the treatment of HCV‐infected patients, and these would be potent inhibitors of HCV and have less adverse events.

【 授权许可】

Unknown